Celmatix Revenue and Competitors
Estimated Revenue & Valuation
- Celmatix's estimated annual revenue is currently $4.5M per year.
- Celmatix's estimated revenue per employee is $155,000
- Celmatix's total funding is $88M.
Employee Data
- Celmatix has 29 Employees.
- Celmatix grew their employee count by -6% last year.
Celmatix's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder & CEO | Reveal Email/Phone |
2 | COO / CFO | Reveal Email/Phone |
3 | VP Biological Sciences | Reveal Email/Phone |
4 | General Counsel | Reveal Email/Phone |
5 | Chief Scientific Officer | Reveal Email/Phone |
6 | Director Clinical Research Operations | Reveal Email/Phone |
7 | Senior Manager, Medical Communications | Reveal Email/Phone |
8 | Senior FullStack RoR Developer on behalf South Geeks | Reveal Email/Phone |
9 | CBO | Reveal Email/Phone |
10 | Sr. System Administrator | Reveal Email/Phone |
Celmatix Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | 0% | N/A | N/A |
#2 | $3.7M | 24 | 41% | $44M | N/A |
#3 | $6.2M | 40 | -7% | N/A | N/A |
#4 | $42M | 271 | -1% | N/A | N/A |
#5 | $12.7M | 82 | 0% | $10M | N/A |
#6 | $2.5M | 16 | 0% | N/A | N/A |
#7 | $7.5M | 45 | 0% | $51.6M | N/A |
#8 | $0.2M | 1 | -50% | N/A | N/A |
#9 | $4.3M | 26 | -16% | $3.3M | N/A |
#10 | $3.7M | 24 | 4% | N/A | N/A |
What Is Celmatix?
Celmatix is a preclinical-stage women's health biotech focused uniquely on ovarian biology. With a lead program in ovarian senescence and collaborations in PCOS and non-hormonal contraception with industry leaders, Celmatix is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in ovarian health. For more information visit www.celmatix.com.
keywords:N/A
$88M
Total Funding
29
Number of Employees
$4.5M
Revenue (est)
-6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Celmatix News
... a new biotech startup called Celmatix wants to improve women's ovarian ... life, according to Piraye Beim, founder and CEO of Celmatix.
Celmatix plans on starting clinical trials of its menopause-delaying drug in 2023. The trials will begin with women undergoing chemotherapy,...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.9M | 29 | -3% | N/A |
#2 | $4.2M | 29 | -29% | N/A |
#3 | $2M | 29 | 32% | $14.1M |
#4 | $5.5M | 29 | 0% | N/A |
#5 | $2M | 29 | -17% | $47.3M |